AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
Completed
Avexa
Phase 2
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is
in treating HIV-1 infected people who have failed treatment with lamivudine.
A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
Completed
Avexa
Phase 1
The purpose of this study is to confirm that apricitabine does not induce any clinically
significant effect upon electrocardiogram (ECG) parameters at doses consistent with the
maximum exposure expected to occur in clinical practice.
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
Completed
Avexa
Phase 1
The aim of the study is to see if apricitabine or tipranavir affect the levels of each other
in the blood (pharmacokinetic interaction) when they are dosed together.
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
Completed
Avexa
Phase 2
The study will examine how safe and effective apricitabine is when given long term (as
ongoing treatment) to HIV patients who have already completed the AVX-201 trial
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Terminated
Avexa
Phase 2/Phase 3
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often
included as part of patients' treatment, but many HIV-infected patients develop resistance to
commonly used NRTIs such as lamivudine (3TC) and emtricitabine (FTC). This study will examine
whether including apricitabine as part of patients' treatment is more effective than
including lamivudine,when patients change treatment because of drug resistance.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
